Advertisement

Topics

ACC program to reduce CVD in type 2 diabetes gets support from industry

08:00 EDT 20 Aug 2017 | Healio

Boehringer Ingelheim and Eli Lilly announced their support of the American College of Cardiology program to address CV risk and mortality in people with type 2 diabetes. “The ACC encourages efforts nationwide and globally to educate and communicate to [CV] health care providers and scientists about innovative advances in [CV] risk reduction in type 2 diabetes. This is the first stage in a longer-term process of optimizing [CV] risk reduction in these complex patient populations,” Nathan D. Wong, PhD, MPH, FACC, professor and director of the Heart Disease Prevention Program at University of California, Irvine School of Medicine, said in the release.

Original Article: ACC program to reduce CVD in type 2 diabetes gets support from industry

NEXT ARTICLE

More From BioPortfolio on "ACC program to reduce CVD in type 2 diabetes gets support from industry"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Cardiology
Cardiology is a specialty of internal medicine.  Cardiac electrophysiology : Study of the electrical properties and conduction diseases of the heart. Echocardiography : The use of ultrasound to study the mechanical function/physics of the h...